Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus
JCI Insight, Volume 2, No. 6, Article e83527, Year 2017
Notification
URL copied to clipboard!
Description
Chikungunya virus (CHIKV) is rapidly spreading across the globe, and millions are infected. Morbidity due to this virus is a serious threat to public health, but at present, there is no vaccine against this debilitating disease. We have recently developed a number of vaccine candidates, and here we have evaluated 3 of them in a nonhuman primate model. A single immunization with an attenuated strain of CHIKV (Δ5nsP3), a homologous prime-boost immunization with a DNA-launched RNA replicon encoding CHIKV envelope proteins (DREP-E), and a DREP-E prime followed by a recombinant modified vaccinia virus Ankara encoding CHIKV capsid and envelope (MVA-CE) boost all induced protection against WT CHIKV infection. The attenuated Δ5nsP3 virus proved to be safe and did not show any clinical signs typically associated with WT CHIKV infections such as fever, skin rash, lymphopenia, or joint swelling. These vaccines are based on an East/Central/South African strain of Indian Ocean lineage, but they also generated neutralizing antibodies against an isolate of the Asian genotype that now is rapidly spreading across the Americas. These results form the basis for clinical development of an efficacious CHIKV vaccine that generates both humoral and cellular immunity with long-term immunological memory. © 2017 American Society for Clinical Investigation. All rights reserved.
Authors & Co-Authors
Roques, Pierre A.
France, Fontenay-aux-roses
Immunologie Des Maladies Virales, Auto-immunes, Hematologiques et Bacteriennes
France, Gif-sur-yvette
Institut Des Maladies Emergentes et Des Thérapies Innovantes
Ljungberg, Karl
Sweden, Stockholm
Karolinska Institutet
Kümmerer, Beate Mareike
Germany, Bonn
Universität Bonn
Dereuddre-Bosquet, Nathalie
France, Fontenay-aux-roses
Immunologie Des Maladies Virales, Auto-immunes, Hematologiques et Bacteriennes
France, Gif-sur-yvette
Institut Des Maladies Emergentes et Des Thérapies Innovantes
Meinke, Andreas L.
Unknown Affiliation
Estéban, Mariano J.
Spain, Madrid
Consejo Superior de Investigaciones Científicas
Merits, Andres
Estonia, Tartu
Tartu Ülikool
Le-Grand, Roger
France, Fontenay-aux-roses
Immunologie Des Maladies Virales, Auto-immunes, Hematologiques et Bacteriennes
France, Gif-sur-yvette
Institut Des Maladies Emergentes et Des Thérapies Innovantes
Liljeström, Peter
Sweden, Stockholm
Karolinska Institutet
Statistics
Citations: 58
Authors: 9
Affiliations: 6
Identifiers
Doi:
10.1172/jci.insight.83527
ISSN:
23793708
Research Areas
Genetics And Genomics
Maternal And Child Health